Shares of Henry Schein, Inc. (NASDAQ:HSIC) gapped down prior to trading on Wednesday . The stock had previously closed at $74.20, but opened at $71.10. Henry Schein shares last traded at $67.58, with a volume of 4007142 shares changing hands.
Several analysts recently commented on the company. Royal Bank Of Canada reduced their target price on Henry Schein from $91.00 to $82.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 7th. Jefferies Group reiterated a “hold” rating and issued a $89.00 target price on shares of Henry Schein in a report on Friday, October 20th. Credit Suisse Group reiterated a “hold” rating and issued a $87.50 target price on shares of Henry Schein in a report on Tuesday, August 29th. Stephens assumed coverage on Henry Schein in a report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 target price on the stock. Finally, Morgan Stanley cut Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price on the stock. in a report on Wednesday. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $88.36.
The stock has a market capitalization of $11,176.72, a price-to-earnings ratio of 19.98, a PEG ratio of 2.00 and a beta of 0.99. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30.
Henry Schein declared that its board has initiated a share repurchase program on Monday, September 18th that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.
In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the transaction, the director now directly owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.19% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Henry Schein by 3.0% during the second quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock worth $1,479,959,000 after purchasing an additional 236,862 shares during the period. FMR LLC raised its position in shares of Henry Schein by 0.4% during the second quarter. FMR LLC now owns 6,921,367 shares of the company’s stock worth $1,266,749,000 after purchasing an additional 24,935 shares during the period. BlackRock Inc. raised its position in shares of Henry Schein by 1.8% during the second quarter. BlackRock Inc. now owns 5,696,685 shares of the company’s stock worth $1,042,607,000 after purchasing an additional 101,406 shares during the period. Alecta Pensionsforsakring Omsesidigt raised its position in shares of Henry Schein by 112.0% during the third quarter. Alecta Pensionsforsakring Omsesidigt now owns 5,313,980 shares of the company’s stock worth $435,693,000 after purchasing an additional 2,806,990 shares during the period. Finally, Mackenzie Financial Corp raised its position in shares of Henry Schein by 106.0% during the third quarter. Mackenzie Financial Corp now owns 3,938,233 shares of the company’s stock worth $322,896,000 after purchasing an additional 2,026,867 shares during the period. Hedge funds and other institutional investors own 91.75% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.